Cam we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue?
Cam we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue?
复制标题
DOI:
10.1002/(sici)1097-0347(199803)20:2
复制
发表时间:
1998-03-01
影响因子:
2.9
通讯作者:
Wolf, PJ
中科院分区:
文献类型:
--
作者:
Byers, RM;El-Naggar, AK;Wolf, PJ
Background. When to do a neck dissection as part of the surgical treatment for a patient with squamous carcinoma of the oral tongue is controversial, particularly when the primary can De resected without entering the neck. if the patient who is al high risk for having occult nodal disease in the neck can De identified, node dissection with the glossectomy could be justified. To better identify patients for this procedure, we correlated various tumor and patient factors along with preoperative diagnostic studies with the presence or absence of pathologically positive nodes in a group of patients who underwent node dissection.Methods, Ninety-one previously untreated patients with biopsy-proved squamous carcinoma of the oral tongue were prospectively studied, All patients had a glossectomy and neck dissection as their initial treatment. The pathology findings (ie, lymph nodes with squamous cancer) were correlated with many preoperative and intraoperative factors, and a statistical analysis was made.Results. The use of computed tomography and ultrasound was not better than the clinical examination in determining the presence or absence of nodal metastases. The best predictors were depth of muscle invasion, double DNA aneuploidy, and histologic differentiation of the tumor.Conclusions. All patients with stage T2-T4 squamous cancers of the oral tongue should have an elective dissection of the neck. Patients with T1NO cancer who have a double DNA-aneuploid tumor, depth of muscle invasion > 4 mm, or have a poorly differentiated cancer should definitely undergo elective neck dissection. Ultrasound and computed tomography are of little value in predicting which patients have positive nodes. (C) 1998 John Wiley & Sons, Inc.